Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$46.51 -0.5%	$39.54	$21.72 ▼ $48.68	$8.83B	1.15	2.55 million shs	2.14 million shs
HRMY Harmony Biosciences	$35.20 -3.4%	$33.82	$26.47 ▼ $41.61	$2.02B	0.83	634,505 shs	701,636 shs
RVMD Revolution Medicines	$38.30 -1.9%	$39.16	$29.17 ▼ $62.40	$7.13B	1.06	1.62 million shs	2.14 million shs
TGTX TG Therapeutics	$37.91 -3.3%	$36.33	$16.65 ▼ $46.48	$6.02B	1.91	2.85 million shs	1.79 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	-0.76%	+1.02%	+16.65%	+38.00%	+66.99%
HRMY Harmony Biosciences	+3.46%	+6.12%	+12.20%	+28.00%	+10.13%
RVMD Revolution Medicines	+1.69%	+1.43%	-0.23%	+6.23%	-15.88%
TGTX TG Therapeutics	+0.90%	+4.04%	+11.97%	+2.27%	+77.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.6251 of 5 stars	4.5	1.0	3.9	3.1	3.3	0.6
HRMY Harmony Biosciences	4.801 of 5 stars	4.5	1.0	0.0	3.4	3.3	4.4
RVMD Revolution Medicines	4.5564 of 5 stars	4.5	3.0	4.7	2.6	1.7	0.0
TGTX TG Therapeutics	3.4049 of 5 stars	2.4	0.0	3.5	1.6	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$61.20	31.58% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.33	45.83% Upside
RVMD Revolution Medicines	3.00	Buy	$68.91	79.92% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	15.54% Upside

Current Analyst Ratings Breakdown

Latest HRMY, TGTX, RVMD, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	RVMD Revolution Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$65.00
7/14/2025	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $68.00
7/14/2025	BBIO BridgeBio Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
7/11/2025	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$58.00 ➝ $67.00
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$33.00
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
7/9/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$60.00
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	39.80	N/A	N/A	($7.71) per share	-6.03
HRMY Harmony Biosciences	$714.73M	2.83	$2.95 per share	11.95	$11.56 per share	3.04
RVMD Revolution Medicines	$11.58M	616.07	N/A	N/A	$13.47 per share	2.84
TGTX TG Therapeutics	$329M	18.29	$0.12 per share	323.77	$1.43 per share	26.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.44	11.32	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	157.96	37.91	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest HRMY, TGTX, RVMD, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.50	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	RVMD Revolution Medicines	-$1.14	N/A	N/A	N/A	$0.50 million	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
8/5/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
HRMY Harmony Biosciences	0.22	3.67	3.63
RVMD Revolution Medicines	N/A	13.46	13.46
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
HRMY Harmony Biosciences	86.23%
RVMD Revolution Medicines	94.34%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
HRMY Harmony Biosciences	23.60%
RVMD Revolution Medicines	8.20%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

HRMY, TGTX, RVMD, and BBIO Headlines

Recent News About These Companies

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Hussman Strategic Advisors Inc.

July 18 at 10:39 AM | marketbeat.com

Jackson Creek Investment Advisors LLC Has $1.40 Million Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 18 at 10:08 AM | marketbeat.com

Edgestream Partners L.P. Increases Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 18 at 5:02 AM | marketbeat.com

Sigma Planning Corp Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 17 at 5:25 AM | marketbeat.com

Bank of New York Mellon Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 15 at 3:35 AM | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Upgraded to Hold at The Goldman Sachs Group

July 13, 2025 | americanbankingnews.com

TG Therapeutics (TGTX) Gets a Hold from Goldman Sachs

July 12, 2025 | theglobeandmail.com

Banque Pictet & Cie SA Acquires Shares of 13,151 TG Therapeutics, Inc. (NASDAQ:TGTX)

July 11, 2025 | marketbeat.com

TG Therapeutics Joins Rank Of Stocks With RS Ratings Over 90

July 10, 2025 | msn.com

TG Therapeutics Joins Elite List Of Stocks With 95-Plus Composite Rating

July 10, 2025 | msn.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Recommendation of "Moderate Buy" from Analysts

July 10, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Earns Neutral Rating from Analysts at The Goldman Sachs Group

July 10, 2025 | marketbeat.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Position Increased by Allspring Global Investments Holdings LLC

July 9, 2025 | marketbeat.com

Axsome Therapeutics Sees Relative Strength Rating Climb To 79

July 8, 2025 | msn.com

Penserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Increases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 8, 2025 | marketbeat.com

New York State Teachers Retirement System Boosts Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 7, 2025 | marketbeat.com

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5, 2025 | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2, 2025 | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY, TGTX, RVMD, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$46.51 -0.23 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$47.18 +0.68 (+1.45%)

As of 06:41 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Harmony Biosciences NASDAQ:HRMY

$35.20 -1.23 (-3.38%)

Closing price 04:00 PM Eastern

Extended Trading

$35.48 +0.28 (+0.80%)

As of 06:28 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Revolution Medicines NASDAQ:RVMD

$38.30 -0.75 (-1.92%)

Closing price 04:00 PM Eastern

Extended Trading

$38.30 0.00 (0.00%)

As of 04:20 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

TG Therapeutics NASDAQ:TGTX

$37.91 -1.28 (-3.27%)

Closing price 04:00 PM Eastern

Extended Trading

$37.95 +0.04 (+0.11%)

As of 06:32 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time